Biologic Brands

Groundbreaking anti-VEGF biologic cancer therapy (bevacizumab) developed by Genentech and owned by Roche, FDA approved February 26, 2004, that reached peak global sales of $7.1 billion in 2019 and now faces biosimilar competition including Mvasi (Amgen) and multiple other approved alternatives.

Prescription biologic medication treating psoriasis, psoriatic arthritis, and other autoimmune conditions.

Blockbuster biologic medication (dupilumab) co-developed by Sanofi and Regeneron Pharmaceuticals. FDA approved in 2017. Over 1.4 million active patients worldwide. Global net sales of $17.8 billion in 2025.

Groundbreaking HER2-targeted biologic cancer therapy (trastuzumab) developed by Genentech and owned by Roche, FDA approved September 25, 1998, that transformed the treatment of HER2-positive breast cancer and now faces biosimilar competition from multiple approved alternatives.

Prescription immunotherapy medication for treating various cancers by activating the immune system, manufactured and marketed by Merck & Co.

Sanofi Genzyme's high-efficacy anti-CD52 monoclonal antibody (alemtuzumab) for active relapsing-remitting multiple sclerosis, FDA approved November 14, 2014, reserved for patients with inadequate response to two or more disease-modifying therapies due to its serious risk profile and REMS program.

Prescription biologic medication for treating age-related macular degeneration and diabetic retinopathy, manufactured and marketed by Novartis.

Roche's HER2-targeted biologic (pertuzumab) developed by Genentech, FDA approved June 8, 2012, that targets a different HER2 domain than Herceptin and is used in combination with Herceptin and chemotherapy for HER2-positive breast cancer in both metastatic and early-stage settings.

Roche's anti-CD20 chimeric monoclonal antibody (rituximab) co-developed by Genentech and IDEC Pharmaceuticals, FDA approved November 26, 1997, as the first monoclonal antibody approved for cancer treatment, now facing biosimilar competition from Truxima, Ruxience, and Riabni.